Can Ascendis Pharma A/S – American Depositary Shares (NASDAQ:ASND)’s Tomorrow be Different? The Stock Had Increase in Shorts

September 16, 2018 - By James Douglas

The stock of Ascendis Pharma A/S – American Depositary Shares (NASDAQ:ASND) registered an increase of 18.19% in short interest. ASND’s total short interest was 343,100 shares in September as published by FINRA. Its up 18.19% from 290,300 shares, reported previously. With 116,300 shares average volume, it will take short sellers 3 days to cover their ASND’s short positions. The short interest to Ascendis Pharma A/S – American Depositary Shares’s float is 1.57%.

The stock decreased 1.17% or $0.81 during the last trading session, reaching $68.34. About 120,337 shares traded. Ascendis Pharma A/S (NASDAQ:ASND) has risen 123.84% since September 16, 2017 and is uptrending. It has outperformed by 108.22% the S&P500.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. The company has market cap of $2.86 billion. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. It currently has negative earnings. The firm is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Coverage

Among 6 analysts covering Ascendis Pharma (NASDAQ:ASND), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Ascendis Pharma had 9 analyst reports since March 20, 2018 according to SRatingsIntel. The rating was maintained by Wedbush on Tuesday, May 15 with “Buy”. The company was maintained on Wednesday, April 4 by Wedbush. The stock of Ascendis Pharma A/S (NASDAQ:ASND) has “Hold” rating given on Thursday, May 31 by Leerink Swann. On Monday, March 19 the stock rating was maintained by Wedbush with “Buy”. The rating was maintained by Credit Suisse with “Outperform” on Tuesday, March 20. The stock of Ascendis Pharma A/S (NASDAQ:ASND) earned “Buy” rating by J.P. Morgan on Monday, May 14. On Thursday, August 30 the stock rating was maintained by Stifel Nicolaus with “Buy”.

More recent Ascendis Pharma A/S (NASDAQ:ASND) news were published by: Globenewswire.com which released: “Ascendis Pharma A/S Reports Second Quarter 2018 Financial Results” on August 29, 2018. Also Nasdaq.com published the news titled: “Ascendis Pharma A/S Announces Upcoming Investor Presentations” on August 31, 2018. Nasdaq.com‘s news article titled: “Ascendis Pharma A/S Announces Presentations on Technology and Rare Disease Endocrinology Pipeline at …” with publication date: September 06, 2018 was also an interesting one.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.